Table 3.
Cases avoided with RZV vaccination vs. no vaccination by age cohort, in the mass vaccination setting (base case)
| Age cohort (years) |
|||||
| N (%) |
50–59 |
60–69 |
70–79 |
80+ |
Total (≥50 years) |
| HZ cases avoided | 238,301 (54.7%) | 132,179 (30.3%) | 45,100 (10.4%) | 20,101 (4.6%) | 435,681 (100.0%) |
| PHN cases avoided | 21,397 (41.5%) | 16,818 (32.6%) | 7,213 (14.0%) | 6,131 (11.9%) | 51,558 (100.0%) |
| HZ-related complications other than PHN avoided | 8,578 (54.6%) | 4,984 (31.7%) | 1,618 (10.3%) | 523 (3.3%) | 15,703 (100.0%) |
| Ocular | 1,952 (57.9%) | 985 (29.2%) | 352 (10.4%) | 80 (2.4%) | 3,370 (100.0%) |
| Neurological (meningitis) | 683 (65.2%) | 303 (28.9%) | 22 (2.1%) | 40 (3.8%) | 1,048 (100.0%) |
| Auricular | 4,076 (54.3%) | 2,415 (32.2%) | 734 (9.8%) | 281 (3.7%) | 7,507 (100.0%) |
| Other | 1,868 (49.4%) | 1,280 (33.9%) | 510 (13.5%) | 121 (3.2%) | 3,779 (100.0%) |
| HZ-related deaths avoided† |
3 (13.3%) |
6 (30.6%) |
5 (24.6%) |
6 (31.5%) |
19 (100.0%) |
| Healthcare resource utilization avoided | |||||
| Hospitalizations | 5,597 (39.3%) | 4,807 (33.7%) | 2,214 (15.5%) | 1,628 (11.4%) | 14,247 (100.0%) |
| Outpatient visits | 566,325 (54.9%) | 312,422 (30.3%) | 106,026 (10.3%) | 46,615 (4.5%) | 1,031,387 (100.0%) |
HZ: herpes zoster; PHN: postherpetic neuralgia; RZV: recombinant zoster vaccine; YOA: years of age.
The total cohort vaccinated was 3,479,000 in the mass vaccination setting. Small discrepancies between subgroups and total cases may be present due to rounding.
†A greater number and proportion of HZ-related deaths would be avoided in the older cohorts compared to the 50–59 YOA cohort, as (i) the estimated HZ-related death probability remains as 0% in the current model until the cohort reaches 70 YOA and older, (ii) RZV efficacy may wane over time, and (iii) not all vaccinated individuals in the 50–69 YOA cohort will reach 70–79 or 80+ YOA